| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | -0.02 | 0.5 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.028 | 0.5 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.5 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | 0.031 | 0.6 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | 0.029 | 0.6 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.032 | 0.6 |